CompletedPhase 2

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

United States11 participantsStarted 2005-06

Plain-language summary

The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.

Who can participate

Age range12 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Lung transplant recipients \> 3 months after transplant surgery * Immunoglobulin G (IgG) \< 500 mg/dL * Stable medical regimen Exclusion Criteria: * Acute rejection * Active infection * Contraindication to IVIG * Pregnancy * Recent thrombotic event

What they're measuring

Number of Clinically Diagnosed Bacterial Infections During the Treatment Period

Timeframe: 3 month

Trial details

NCT IDNCT00115778

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-08

Results submitted2011-06-14

View on ClinicalTrials.gov More Hypogammaglobulinemia trials